SBIR-STTR Award

A Neonatal Cerebral Blood Flow Monitor Based on Mems Ultrasound
Award last edited on: 4/11/16

Sponsored Program
SBIR
Awarding Agency
NIH : NICHD
Total Award Amount
$447,028
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
David F Lemmerhirt

Company Information

Sonetics Ultrasound Inc

704 Airport Boulevard Suite 6
Ann Arbor, MI 48108
   (734) 260-4800
   crich@soneticsultrasound.com
   soneticsultrasound.com
Location: Single
Congr. District: 12
County: Washtenaw

Phase I

Contract Number: 1R43HD069250-01
Start Date: 9/15/11    Completed: 8/31/13
Phase I year
2011
Phase I Amount
$246,888
The goal of the proposed program is to address several technical feasibility questions (in Phase I), and then demonstrate (in a subsequent Phase II) a safe, compact patch-like monitoring device for directly measuring blood flow to the brain in very low birth weight (VLBW, <1500gm) infants. In Phase I, the accuracy of 3D Doppler techniques will be evaluated for the vessel sizes and geometries specific to the neonatal brain, and the feasibility will be determined for implementing these techniques using a compact MEMS-based ultrasound transducer module. In Phase II, a full-scale transducer prototype will be developed and demonstrated in animal and/or clinical studies. Finally, in Phase III the monitoring hardware and software will be commercialized and translated to the clinical market, likely in partnership with manufacturers of existing neonatal monitoring equipment. The clinical market stands to benefit greatly from this innovation, given that nearly 64,000 VLBW infants are born in the U.S. each year. Many of these fragile patients will sustain devastating brain injuries during the first days and weeks of life due to abnormal blood flow to the brain. Currently, brain injuries cause 5-10% of VLBW survivors to suffer from cerebral palsy and many more will develop cognitive or behavioral abnormalities in later life. Regular monitoring of blood flow to the neonatal brain would provide physicians the information needed to intervene early, reducing the likelihood of lasting injury. This would clearly have immense human benefit and would also reduce healthcare spending, given recent estimates that suggest the lifetime cost of care for each cerebral palsy patient will exceed $1M.

Public Health Relevance:
Potential benefits to public health from the successful development of Sonetics'novel ultrasound-based neonatal cerebral blood flow monitor include: higher survival rates for very low birth weight infants, reduced prevalence of cerebral palsy and other developmental problems resulting from neonatal brain injuries, and reduced health-care costs for society as a whole. Furthermore, if accurate direct blood flow monitoring becomes more widely deployed, health outcomes will improve for additional patient populations such as those with peripheral arterial disease.

Thesaurus Terms:
3-D Images;3-D Image;3d Image;3d Images;Acquired Brain Injury;Address;Aged 65 And Over;Anatomic;Anatomical Sciences;Anatomy;Animals;Behavioral;Blood Flow;Body Tissues;Brain;Brain Injuries;Brain Nervous System;Caring;Cerebral Brain Hemorrhage;Cerebral Hemorrhage;Cerebral Palsy;Cerebral Parenchymal Hemorrhage;Cerebral Hemisphere Hemorrhage;Cerebrovascular Circulation;Cerebrum;Cerebrum Hemorrhage;Clinical;Clinical Research;Clinical Study;Cognitive;Computer Software;Data;Development;Devices;Doppler Ultrasound;Echography;Echotomography;Elderly;Elements;Encephalon;Ensure;Equipment;Frequencies (Time Pattern);Frequency;Goals;Head;Health;Health Care Costs;Health Costs;Healthcare;Healthcare Costs;Human;Hydrogen Oxide;Image;Incubators;Infant;Injury;Intracerebral Hemorrhage;Investigators;Loinc Axis 4 System;Laboratories;Legal Patent;Life;Location;Man (Taxonomy);Manufacturer;Manufacturer Name;Marketing;Measurement;Measures;Medical Ultrasound;Methods;Michigan;Modern Man;Monitor;Neonatal;Neonatal Brain Injury;Outcome;Patents;Patients;Performance;Peripheral Arterial Disease;Phase;Physicians;Position;Positioning Attribute;Premature Infant;Prevalence;Public Health;Reproducibility;Research Personnel;Researchers;Safety;Scheme;Societies;Software;Survival Rate;Survivors;Symptoms;System;Techniques;Technology;Testing;Thinking;Thinking, Function;Three-Dimensional Image;Tissues;Transducers;Translating;Tube;Ultrasonic Imaging;Ultrasonic Transducer;Ultrasonogram;Ultrasonography;Ultrasound Diagnosis;Ultrasound Medical Imaging;Ultrasound Test;Ultrasound Transducer;Universities;Vlbw (Human);Very Low Birth Weight Infant;Water;Work;Advanced Age;Base;Brain Damage;Brain Lesion (From Injury);Brain Tissue;Cerebral;Cerebral Blood Flow;Cerebral Circulation;Cerebrocirculation;Computer Program/Software;Design;Designing;Developmental;Diagnostic Ultrasound;Elders;Experiment;Experimental Research;Experimental Study;Flexibility;Flexible;Geriatric;Health Care;Imaging;Improved;Innovate;Innovation;Innovative;Late Life;Later Life;Life Time Cost;Lifetime Cost;Meetings;Monitoring Device;Novel;Older Adult;Older Person;Over 65 Elderly;Patient Population;Peripheral Artery Disease;Portability;Premature Baby;Premature Infant Human;Preterm Baby;Preterm Infant;Preterm Infant Human;Preterm Neonate;Programs;Prototype;Public Health Medicine (Field);Research Study;Senior Citizen;Sonogram;Sonography;Sound Measurement;Thoughts;Ultrasound;Ultrasound Imaging;Ultrasound Scanning;Very Low Birth Weight;Very Low Birth Weight Infant Human

Phase II

Contract Number: 5R43HD069250-02
Start Date: 9/15/11    Completed: 8/31/14
Phase II year
2012
Phase II Amount
$200,140
The goal of the proposed program is to address several technical feasibility questions (in Phase I), and then demonstrate (in a subsequent Phase II) a safe, compact patch-like monitoring device for directly measuring blood flow to the brain in very low birth weight (VLBW, <1500gm) infants. In Phase I, the accuracy of 3D Doppler techniques will be evaluated for the vessel sizes and geometries specific to the neonatal brain, and the feasibility will be determined for implementing these techniques using a compact MEMS-based ultrasound transducer module. In Phase II, a full-scale transducer prototype will be developed and demonstrated in animal and/or clinical studies. Finally, in Phase III the monitoring hardware and software will be commercialized and translated to the clinical market, likely in partnership with manufacturers of existing neonatal monitoring equipment. The clinical market stands to benefit greatly from this innovation, given that nearly 64,000 VLBW infants are born in the U.S. each year. Many of these fragile patients will sustain devastating brain injuries during the first days and weeks of life due to abnormal blood flow to the brain. Currently, brain injuries cause 5-10% of VLBW survivors to suffer from cerebral palsy and many more will develop cognitive or behavioral abnormalities in later life. Regular monitoring of blood flow to the neonatal brain would provide physicians the information needed to intervene early, reducing the likelihood of lasting injury. This would clearly have immense human benefit and would also reduce healthcare spending, given recent estimates that suggest the lifetime cost of care for each cerebral palsy patient will exceed $1M.